Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $22.57 Average PT from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $22.57.

Several analysts have issued reports on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 price target on shares of Neumora Therapeutics in a research note on Thursday, March 28th. William Blair reaffirmed an "outperform" rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. Finally, JPMorgan Chase & Co. lifted their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the company an "overweight" rating in a research report on Monday, March 18th.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors have recently bought and sold shares of NMRA. FMR LLC acquired a new position in Neumora Therapeutics during the third quarter worth approximately $79,360,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST bought a new stake in shares of Neumora Therapeutics during the third quarter worth approximately $46,692,000. Avidity Partners Management LP bought a new stake in shares of Neumora Therapeutics during the third quarter worth approximately $25,398,000. Johnson & Johnson bought a new stake in shares of Neumora Therapeutics during the third quarter worth approximately $12,870,000. Finally, Addis & Hill Inc bought a new stake in shares of Neumora Therapeutics during the first quarter worth approximately $4,187,000. Institutional investors and hedge funds own 47.65% of the company's stock.

Neumora Therapeutics Stock Performance

NMRA stock traded up $0.09 during midday trading on Friday, hitting $9.15. 677,291 shares of the company's stock were exchanged, compared to its average volume of 610,411. The stock's fifty day moving average price is $14.64 and its 200-day moving average price is $14.09. Neumora Therapeutics has a one year low of $8.82 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.05. As a group, research analysts forecast that Neumora Therapeutics will post -1.48 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.